An Extension Study for Subjects Who Are Deriving Benefit With Idelalisib (GS-1101; CAL-101) Following Completion of a Prior Idelalisib Study

Memorial Sloan-Kettering Cancer Center, New York

Weill Medical College of Cornell, New York

Mount Sinai School of Medicine, New York

Long Island Jewish medical Center, New Hyde Park

Center for Cancer & Blood Disorders, PC, Bethesda

Clearview Cancer Institute, Huntsville

Sarah Cannon Research Institute, Nashville

The Ohio State University Medical Center, Columbus

Washington University School of Medicine, St Louis

MD Anderson Cancer and Research Center, Houston

MD Anderson Cancer Center, Houston

Oregon Health & Science University, Portland

Willamette Valley Cancer Institute and Research Center, Springfield

Yakima Regional Cancer Care, Yakima

UCLA, Los Angeles

Stanford Cancer Center, Palo Alto

Dana-Farber Cancer Institute, Boston

University of Wisconsin, Madison